Focused ultrasound–mediated AAV gene therapy: Unlocking a new space in the CNS delivery landscape
Molecular Therapy · 2026-11
DOI: 10.1016/j.ymthe.2026.10.033 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Molecular Therapy, 2026-11. Verfasst von Nick Todd und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Radiology, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts, United States. Electronic address: ntodd1@bwh.h…. Gefördert von: National Institutes of Health.
Abstract (Originalsprache)
Adeno-associated viruses (AAVs) have emerged as the most clinically advanced platform for in vivo gene delivery, enabling durable therapeutic gene expression across a growing number of neurological disorders. However, successful delivery of AAVs to the brain requires navigating trade-offs among three interdependent factors: the vector dose administered, the resulting delivery efficacy within target cells, and the volume of brain tissue that can be effectively covered. While multiple clinical strategies have demonstrated that different positions within this delivery landscape can achieve therapeutic benefit, each approach carries important limitations, including surgical invasiveness, limited regional coverage, peripheral toxicity at high doses, manufacturing burden, or the risks associated with global brain transgene exposure. This review situates focused ultrasound-mediated blood-brain barrier opening (FUS-BBBO) within this broader CNS delivery landscape. Through the distinct mechanical mechanism of microbubble cavitation, FUS transiently and locally increases BBB permeability at user-defined targets, enabling systemically administered AAVs to enter the brain at high local concentrations while limiting transduction of non-targeted regions. We discuss how advances in large-volume sonication and FUS-optimized AAV capsids are converging to define an engineering path toward a clinically translatable delivery paradigm that is non-invasive, regionally selective, and highly efficient.
Autor:innen und Institutionen
- Department of Radiology, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts, United States. Electronic address: ntodd1@bwh.harvard.edu.
- Department of Radiology, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts, United States.
- Amherst College, Amherst, Massachusetts, United States.
- Department of Neurosurgery, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts, United States.
- Department of Neurology, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts, United States.
- Department of Neurosurgery, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts, United States.
Förderung
- National Institutes of Health
Zitieren
APA
Todd, N., Owusu-Yaw, B., Hines, E., Li, Z., McDannold, N., Maguire, C. A., Richardson, R. M., & Bei, F. (2026). Focused ultrasound–mediated AAV gene therapy: Unlocking a new space in the CNS delivery landscape. Molecular Therapy. https://doi.org/10.1016/j.ymthe.2026.10.033
Vancouver
Todd N, Owusu-Yaw B, Hines E, Li Z, McDannold N, Maguire CA, et al. Focused ultrasound–mediated AAV gene therapy: Unlocking a new space in the CNS delivery landscape. Molecular Therapy. 2026. doi:10.1016/j.ymthe.2026.10.033
BibTeX
@article{Todd2026,
author = {Todd, Nick and Owusu-Yaw, Bernie and Hines, Elián and Li, Zhenghui and McDannold, Nathan and Maguire, Casey A and Richardson, R Mark and Bei, Fengfeng},
title = {Focused ultrasound–mediated AAV gene therapy: Unlocking a new space in the CNS delivery landscape},
journal = {Molecular Therapy},
year = {2026},
doi = {10.1016/j.ymthe.2026.10.033}
}
EUVIMED